lambert-eaton syndrome

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:healthcare_organization
gptkbp:bfsLayer 3
gptkbp:bfsParent gptkb:Insurance_Company
gptkbp:affects neuromuscular junction
gptkbp:associated_with small cell lung cancer
thymoma
other malignancies
gptkbp:caused_by autoimmune response
gptkbp:clinical_trial ongoing studies
autonomic dysfunction
reflexes may be diminished
proximal muscle weakness
muscle strength may improve with repeated use
gptkbp:current_use gptkb:Insurance_Company
gptkbp:demographics more common in men
gptkbp:first_described_by Eaton and Lambert
https://www.w3.org/2000/01/rdf-schema#label lambert-eaton syndrome
gptkbp:is_a_route_for antibodies against voltage-gated calcium channels
gptkbp:is_popular_in rare
gptkbp:premiered_on typically between 40 and 60
can occur in adults
gptkbp:research_areas neurology
oncology
immunology
gptkbp:research_focus patient registries
treatment efficacy
genetic predisposition
environmental triggers
quality of life assessments
long-term outcomes
biomarkers for diagnosis
immunological markers
understanding autoimmune mechanisms
gptkbp:social_responsibility variable
electromyography
blood tests for antibodies
gptkbp:symptoms fatigue
muscle weakness
difficulty breathing
difficulty swallowing
dry mouth
muscle cramps
impaired vision
improvement with exercise
gptkbp:treatment gptkb:mycophenolate_mofetil
gptkb:methotrexate
gptkb:physicist
gptkb:vaccine
gptkb:cyclophosphamide
gptkb:rituximab
gptkb:azathioprine
physical therapy
supportive care
monoclonal antibodies
symptomatic treatment
plasma exchange
immunosuppressive drugs
acetylcholinesterase inhibitors
IVIG